Synthesis of 3,5-bis(2-indolyl) pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents

被引:60
作者
Jacquemard, Ulrich [1 ]
Dias, Nathalie [2 ]
Lansiaux, Amelie [2 ]
Bailly, Christian [2 ]
Loge, Cedric [3 ]
Robert, Jean-Michel [3 ]
Lozach, Olivier [4 ]
Meijer, Laurent [4 ]
Merour, Jean-Yves [1 ]
Routier, Sylvain [1 ]
机构
[1] Univ Orleans, CNRS, UMR 6005, Inst Chim Organ & Analyt, F-45067 Orleans 2, France
[2] INSERM, U 837, IRCL, F-59045 Lille, France
[3] Univ Nantes, Nantes Atlantique Univ, Dept Pharmacochim, BioCiT EA 1155,UFR Sci Pharmaceut, F-44000 Nantes, France
[4] CNRS, Amyloids & Cell Div Cycle Grp, F-29680 Roscoff, France
关键词
indole; pyridine; CDK inhibitors; cytotoxicity; anticancer agent;
D O I
10.1016/j.bmc.2008.03.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We here report the synthesis and biological evaluation of new 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl] pyridine designed as potential CDK inhibitors. Indole, 5-hydroxyindole, and phenol derivatives were used to generate three substitutions of the pyridine. The resulting skeletons were successively exploited to introduce various dimethylaminoalkyl side chains by Williamson type reactions. The synthesis includes Stille or Suzuki type reactions, which were realized on the 3,5-dibromopyridine. The preparation and the use of stannylindoles in mono or bis cross-coupling reactions were also described and each step was optimized and detailed. Kinase assays were realized and shown that nude compounds 7, 18, and 25 inhibited CDK1 in the 0.3 - 0.7 micromolar range with a good selectivity over GSK-3. Cytotoxicity against CEM human leukemia cells was evaluated with IC50 values in the 5 - 15 micromolar range. Precise structure - activity relationships were delineated. Molecular modeling and docking solutions were proposed to complete the studies and to explain the observed SAR in the CDK assays. (c) 2008 Published by Elsevier Ltd.
引用
收藏
页码:4932 / 4953
页数:22
相关论文
共 45 条
  • [1] ATTIA A, 1995, PHARMAZIE, V50, P455
  • [2] IPy2BF4-promoted intramolecular addition of masked and unmasked anilines to alkynes:: Direct assembly of 3-iodoindole cores
    Barluenga, J
    Trincado, M
    Rubio, E
    González, JM
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (21) : 2406 - 2409
  • [3] The Protein Data Bank
    Berman, HM
    Westbrook, J
    Feng, Z
    Gilliland, G
    Bhat, TN
    Weissig, H
    Shindyalov, IN
    Bourne, PE
    [J]. NUCLEIC ACIDS RESEARCH, 2000, 28 (01) : 235 - 242
  • [4] Synthesis of novel halopyridinylboronic acids and esters. Part 2: 2,4, or 5-Halopyridin-3-yl-boronic acids and esters
    Bouillon, A
    Lancelot, JC
    Collot, V
    Bovy, PR
    Rault, S
    [J]. TETRAHEDRON, 2002, 58 (17) : 3323 - 3328
  • [5] Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties
    Brachwitz, K
    Voigt, B
    Meijer, L
    Lozach, P
    Schächtele, C
    Molnár, J
    Hilgeroth, A
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (05) : 876 - 879
  • [6] Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis
    Bramson, HN
    Corona, J
    Davis, ST
    Dickerson, SH
    Edelstein, M
    Frye, SV
    Gampe, RT
    Harris, PA
    Hassell, A
    Holmes, WD
    Hunter, RN
    Lackey, KE
    Lovejoy, B
    Luzzio, MJ
    Montana, V
    Rocque, WJ
    Rusnak, D
    Shewchuk, L
    Veal, JM
    Walker, DH
    Kuyper, LF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) : 4339 - 4358
  • [7] Imidazo[1,2-b]pyridazines:: a potent and selective class of cyclin-dependent kinase inhibitors
    Byth, KF
    Cooper, N
    Culshaw, JD
    Heaton, DW
    Oakes, SE
    Minshull, CA
    Norman, RA
    Pauptit, RA
    Tucker, JA
    Breed, J
    Pannifer, A
    Rowsell, S
    Stanway, JJ
    Valentine, AL
    Thomas, AP
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) : 2249 - 2252
  • [8] Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity
    Chu, Xin-Jie
    DePinto, Wanda
    Bartkovitz, David
    So, Sung-Sau
    Vu, Binh T.
    Packman, Kathryn
    Lukacs, Christine
    Ding, Qingjie
    Jiang, Nan
    Wang, Ka
    Goelzer, Petra
    Yin, Xuefeng
    Smith, Melissa A.
    Higgins, Brian X.
    Chen, Yingsi
    Xiang, Qing
    Moliterni, John
    Kaplan, Gerald
    Graves, Bradford
    Lovey, Allen
    Fotouhi, Nader
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (22) : 6549 - 6560
  • [9] VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD
    CLARK, M
    CRAMER, RD
    VANOPDENBOSCH, N
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) : 982 - 1012
  • [10] Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate
    Davies, TG
    Tunnah, P
    Meijer, L
    Marko, D
    Eisenbrand, G
    Endicott, JA
    Noble, MEM
    [J]. STRUCTURE, 2001, 9 (05) : 389 - 397